1. A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
2. The sustained release oral dosage formulation of claim 1, wherein the formulation further provides delayed release of the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 after ingestion of the formulation.
3. The sustained release oral dosage formulation of claim 2, wherein release is substantially delayed until the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 reaches the ileum of the intestine.
4. The sustained release oral dosage formulation of claim 2, further comprising an enteric coating.
5. The sustained release oral dosage formulation of claim 1, comprising the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 dispersed within a matrix.
6. The sustained release oral dosage formulation of claim 5, wherein the matrix releasably binds the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
7. The sustained release oral dosage formulation of claim 6, wherein the matrix provides for release of the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 via diffusion.
8. The sustained release oral dosage formulation of claim 6, wherein the matrix provides for release of the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 via disintegration of the matrix.
9. The sustained release oral dosage formulation of claim 6, wherein the dosage form further comprises a permeable framework around the matrix.
10. The sustained release oral dosage formulation of claim 5, wherein the matrix comprises a wax matrix.
11. The sustained release oral dosage formulation of claim 10, wherein the wax matrix comprises a wax and an oil.
12. The sustained release oral dosage formulation of claim 5, further comprising a glyceride.
13. The sustained release oral dosage formulation of claim 5, further comprising a gelatin capsule, the wax matrix being disposed in the gelatin capsule.
14. The sustained release oral dosage formulation of claim 13, wherein the gelatin capsule is a hard gelatin capsule.
15. The sustained release oral dosage formulation of claim 5, wherein the formulation is semi-solid at body temperature.
16. The sustained release oral dosage formulation of claim 13, wherein the gelatin capsule is a soft gelatin capsule.
17. The sustained release oral dosage formulation of claim 1, wherein the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 is contained in granules coated with a polymer.
18. The sustained release oral dosage formulation of claim 17, wherein the polymer comprises an insoluble polymer selected from the group consisting of methacrylic acid esters, polyvinyl esters, polyvinyl acetals, polyacrylic acid esters, and butadiene styrene copolymers.
19. The sustained release oral dosage formulation of claim 18, wherein the polymer comprises methacrylic acid esters.
20. The sustained release oral dosage formulation of claim 19, further comprising trimethylammonioethyl methacrylate chlorides.
21. The sustained release oral dosage formulation of claim 1, comprising 1 to 50 mcg per unit dose of the 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
22. The sustained release oral dosage formulation of claim 1, wherein the sustained release is effected over a period of at least four hours.
23. The sustained release oral dosage formulation of claim 1, comprising 25-hydroxyvitamin D3.
24. The sustained release oral dosage formulation of claim 1, wherein the release of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 avoids supraphysiologic surges in intralumenal, intracellular, andor blood levels of 25-hydroxyvitamin D.
25. A sustained release oral dosage formulation of 25-hydroxyvitamin D3 dispersed within a wax matrix comprising a wax, an oil, and a glyceride, and disposed within a capsule.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A reinforced areal implant, comprising a net-type basic structure having a pore size in the mange of 1.5 mm to 4.0 mm and textile strengthening elements whose bending resistance, measured in a three-point flexibility test at a support length of 20 mm, is in the range of 0.015 Nmm to 0.4 Nmm, where the textile strengthening elements form a net-type strengthening structure with a pore size in the range of 5 mm to 30 mm, said pore size being a multiple of the pore size of the basic structure.
2. The implant according to claim 1, wherein the basic structure comprises knitware.
3. The implant according to claim 2, wherein the strengthening elements are laid or knitted into the basic structure.
4. The implant according to claim 1, wherein the basic structure comprises non-absorbable material or very slowly absorbable material that retains at least 50% of its initial tear-strength after 180 days in-vivo.
5. The implant according to claim 4, wherein the basic structure comprises multi-filament yarn made of polypropylene.
6. The implant according to claim 1, wherein the basic structure comprises absorbable multi-filament yarn.
7. The implant according to claim 1, wherein the basic structure has at least one component selected from the group consisting of yarn of poly-p-dioxanone, yarn of a copolymer of L-lactide and glycolide in the ratio of 10:90, yarn of a copolymer of L-lactide and glycolide in the ratio of 95:5, yarn of a copolymer of L-lactide and glycolide in a different ratio.
8. The implant according to claim 1, wherein the strengthening elements comprise at least one component selected from the group consisting of pure mono-filaments, twisted mono-filaments, twisted multi-filament yarns, and composite multi-filament yarns.
9. The implant according to claim 8, wherein the strengthening elements comprise at least one component selected from the group consisting of mono-filaments of polypropylene, multi-filament yarns of polypropylene, mono-filaments of poly-p-dioxanone, multi-filament yarns of a copolymer of L-lactide and glycolide in the ratio of 10:90, and yarns of poly-p-dioxanone.
10. The implant according to claim 1, wherein at least part of the strengthening elements has a color different from that of the basic structure.